Eyelash Transplant & Eyebrow Transplant A link to the page on Bauman Medical Group's site specifically for eyelash transplants and eyebrow transplants. Before and After photos, video, side-effects, results and faq's can be found there.
At the 25th Annual Meeting of the American Academy of Cosmetic Surgery in Phoenix AZ, I was given the opportunity to present an update to last year's lecture on Cosmetic and Reconstructive Eyelash Transplantation. Updates on technique (including advanced techniques, like the paired-follicle implantation and 'puppetteering' technique for curl orientation) were discussed. Also presented was a review of the pertinent clinical data that led to the FDA's recent approval of Allergan's eyelash growth drug, Latisse(tm), inclding many before-and-after photos. For information regarding the content of the lecture, please email me at email@example.com.
Latisse (Allergan) contains 0.03% bimatoprost, a synthetic prostamide compound which is also the active ingredient in Lumigan--a common glaucoma drug. Allergan received FDA-approval for Latisse to market the medication as a treatment for eyelash hypotrichosis (thin, short, sparse, weak or inadequate eyelashes). Applied nightly to the lid margin (where the lashes exit the skin), the medication increases the length, density, thickness and pigmentation of the existing lashes within weeks.
At Bauman Medical Group, we've been using non-invasive treatments and eyelash transplants to help women (and even some men) regain, regrow, replace and/or enhance their eyelashes. For more information, visit www.eyelash-transplant.com
In Charla Krupp's new book entitled "How Not To Look Old," she mentions eyelash loss (thinner, weaker, shorter or missing lashes) as a sign of aging and Dr. Bauman's eyelash transplant procedure as a solution. Charla's book is available on Amazon.com at http://www.amazon.com/How-Not-Look-Old-Effortless/dp/0446581143
Speculation about celebrity plastic surgery is always a hot topic. And, while many celebs are denying it, more and more are going under the knife to prevent the 'ravages' of time. Not just facelifts and eyelids, but hair restoration treatments and procedures as well. Actors, politicians and others in the public eye who want to maintain their youthful image often seek the advice and services of cosmetic surgeons.
A well-documented side-effect of anti-glaucoma medications (like Lumigan(R), Xalatan(R) and Travatan(R)) is increased eyelash length, density and pigmentation. These glaucoma drugs all contain active ingredients that fall into the category of Prostaglandin Analogues (or Analogs). Bimatoprost, the active ingredient in Lumigan(R), appears to be one of the more potent stimulators of eyelash growth. Well before the popular formulations of Jan Marini Age Intervention Eyelash, Revitalash and MD Lash Factor were available, doctors were able to write 'off-label' prescriptions for the topical use of medications, like Lumigan(R) for example, for their cosmetic patients who had weak lashes.
In September 2006, the FDA embargoed Jan Marini's Age Intervention Eyelash (JMAIE) product due to problems with 'labelling.' Reformulating the product and packaging, the JMAIE was re-released and distributed starting around February of 2007. It appears that the initial product contained bimatoprost, but the new formulation has a different, perhaps new, prostaglandin analogue.
While the JMAIE was off the market, Revitalash appeared on the scene with an eyelash conditioner formulation which received rave reviews from patients. According to Athena Cosmetics (makers of Revitalash), it appears that Revitalash does contain bimatoprost--but at a much smaller concentration than the drug Lumigan(R). At this time, Revitalash voluntarily no longer distributing their product, but promises to re-release a new formulation shortly.
MD Lash Factor, made by Procyte/Photomedix, also contains a prostaglandin analogue--not bimatoprost, but a 'novel' compound.